MedImmune Appoints Development Leadership Team
This article was originally published in The Pink Sheet Daily
Former Cambridge Antibody Technology exec to oversee product development.
You may also be interested in...
MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.
Deal for Cambridge Antibody Technology, valued at $1.07 bil., will shift focus of AstraZeneca’s pipeline.
Biogen has been granted new US patents for Tecfidera after generics already launched. It's unclear how Biogen will proceed but management could shed more light on the matter during the first quarter call.